BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ohtani N, Kawada N. Role of the Gut-Liver Axis in Liver Inflammation, Fibrosis, and Cancer: A Special Focus on the Gut Microbiota Relationship. Hepatol Commun. 2019;3:456-470. [PMID: 30976737 DOI: 10.1002/hep4.1331] [Cited by in Crossref: 33] [Cited by in F6Publishing: 36] [Article Influence: 11.0] [Reference Citation Analysis]
Number Citing Articles
1 Wu J, Wang Y, Jiang Z. Immune induction identified by TMT proteomics analysis in Fusobacterium nucleatum autoinducer-2 treated macrophages. Expert Review of Proteomics 2020;17:175-85. [DOI: 10.1080/14789450.2020.1738223] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
2 Gwag T, Reddy Mooli RG, Li D, Lee S, Lee EY, Wang S. Macrophage-derived thrombospondin 1 promotes obesity-associated non-alcoholic fatty liver disease. JHEP Rep 2021;3:100193. [PMID: 33294831 DOI: 10.1016/j.jhepr.2020.100193] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
3 Ohtani N, Hara E. Gut-liver axis-mediated mechanism of liver cancer: A special focus on the role of gut microbiota. Cancer Sci 2021. [PMID: 34533882 DOI: 10.1111/cas.15142] [Reference Citation Analysis]
4 De Muynck K, Vanderborght B, Van Vlierberghe H, Devisscher L. The Gut-Liver Axis in Chronic Liver Disease: A Macrophage Perspective. Cells 2021;10:2959. [PMID: 34831182 DOI: 10.3390/cells10112959] [Reference Citation Analysis]
5 Yan S, Yin XM. Gut microbiome in liver pathophysiology and cholestatic liver disease. Liver Res 2021;5:151-63. [PMID: 35355516 DOI: 10.1016/j.livres.2021.08.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Lee NY, Shin MJ, Youn GS, Yoon SJ, Choi YR, Kim HS, Gupta H, Han SH, Kim BK, Lee DY, Park TS, Sung H, Kim BY, Suk KT. Lactobacillus attenuates progression of nonalcoholic fatty liver disease by lowering cholesterol and steatosis. Clin Mol Hepatol 2021;27:110-24. [PMID: 33317254 DOI: 10.3350/cmh.2020.0125] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
7 Qu L, Ma X, Fan D. Ginsenoside Rk3 Suppresses Hepatocellular Carcinoma Development through Targeting the Gut-Liver Axis. J Agric Food Chem 2021;69:10121-37. [PMID: 34415764 DOI: 10.1021/acs.jafc.1c03279] [Reference Citation Analysis]
8 Loilome W, Dokduang H, Suksawat M, Padthaisong S. Therapeutic challenges at the preclinical level for targeted drug development for Opisthorchis viverrini-associated cholangiocarcinoma. Expert Opin Investig Drugs 2021;:1-22. [PMID: 34292795 DOI: 10.1080/13543784.2021.1955102] [Reference Citation Analysis]
9 Wang Y, Zhang Y, Liu Y, Xu J, Liu Y. Gut-Liver Axis: Liver Sinusoidal Endothelial Cells Function as the Hepatic Barrier in Colitis-Induced Liver Injury. Front Cell Dev Biol 2021;9:702890. [PMID: 34336855 DOI: 10.3389/fcell.2021.702890] [Reference Citation Analysis]
10 Qian J, Jiao Y, Wang G, Liu H, Cao X, Yang H. Mechanism of TGF-β1 inhibiting Kupffer cell immune responses in cholestatic cirrhosis. Exp Ther Med 2020;20:1541-9. [PMID: 32742385 DOI: 10.3892/etm.2020.8826] [Reference Citation Analysis]
11 Zhu M, Liu X, Li W, Wang L. Exosomes derived from mmu_circ_0000623-modified ADSCs prevent liver fibrosis via activating autophagy. Hum Exp Toxicol 2020;39:1619-27. [PMID: 32633558 DOI: 10.1177/0960327120931152] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
12 Liu Y, Cavallaro PM, Kim BM, Liu T, Wang H, Kühn F, Adiliaghdam F, Liu E, Vasan R, Samarbafzadeh E, Farber MZ, Li J, Xu M, Mohad V, Choi M, Hodin RA. A role for intestinal alkaline phosphatase in preventing liver fibrosis. Theranostics 2021;11:14-26. [PMID: 33391458 DOI: 10.7150/thno.48468] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Jia W, Rajani C, Xu H, Zheng X. Gut microbiota alterations are distinct for primary colorectal cancer and hepatocellular carcinoma. Protein Cell 2021;12:374-93. [PMID: 32797354 DOI: 10.1007/s13238-020-00748-0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
14 Koumbi L, Eliopoulos AG, Vassilopoulou E. How Diet-Induced Changes in the “Gut-Liver” Axis Affect Chronic Liver Disease Outcome? Livers 2021;1:40-8. [DOI: 10.3390/livers1010004] [Reference Citation Analysis]
15 Liu Y, Li Y, Xia Y, Liu K, Ren L, Ji Y. The Dysbiosis of Gut Microbiota Caused by Low-Dose Cadmium Aggravate the Injury of Mice Liver through Increasing Intestinal Permeability. Microorganisms 2020;8:E211. [PMID: 32033263 DOI: 10.3390/microorganisms8020211] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
16 Sehgal R, Ilha M, Vaittinen M, Kaminska D, Männistö V, Kärjä V, Tuomainen M, Hanhineva K, Romeo S, Pajukanta P, Pihlajamäki J, de Mello VD. Indole-3-Propionic Acid, a Gut-Derived Tryptophan Metabolite, Associates with Hepatic Fibrosis. Nutrients 2021;13:3509. [PMID: 34684510 DOI: 10.3390/nu13103509] [Reference Citation Analysis]
17 Peterson SN, Bradley LM, Ronai ZA. The gut microbiome: an unexpected player in cancer immunity. Curr Opin Neurobiol 2020;62:48-52. [PMID: 31816571 DOI: 10.1016/j.conb.2019.09.016] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
18 Guzzardi MA, La Rosa F, Campani D, Cacciato Insilla A, De Sena V, Panetta D, Brunetto MR, Bonino F, Collado MC, Iozzo P. Maturation of the Visceral (Gut-Adipose-Liver) Network in Response to the Weaning Reaction versus Adult Age and Impact of Maternal High-Fat Diet. Nutrients 2021;13:3438. [PMID: 34684436 DOI: 10.3390/nu13103438] [Reference Citation Analysis]
19 Li Z, Ni M, Yu H, Wang L, Zhou X, Chen T, Liu G, Gao Y. Gut Microbiota and Liver Fibrosis: One Potential Biomarker for Predicting Liver Fibrosis. Biomed Res Int 2020;2020:3905130. [PMID: 32685479 DOI: 10.1155/2020/3905130] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
20 Honda T, Ishigami M, Yamamoto K, Takeyama T, Ito T, Ishizu Y, Kuzuya T, Nakamura M, Kawashima H, Miyahara R, Ishikawa T, Hirooka Y, Fujishiro M. Changes in the gut microbiota after hepatitis C virus eradication. Sci Rep 2021;11:23568. [PMID: 34876650 DOI: 10.1038/s41598-021-03009-0] [Reference Citation Analysis]
21 Hild B, Heinzow HS, Schmidt HH, Maschmeier M. Bile Acids in Control of the Gut-Liver-Axis. Z Gastroenterol 2021;59:63-8. [PMID: 33429452 DOI: 10.1055/a-1330-9644] [Reference Citation Analysis]
22 Zhao J, Miao J, Wei X, Guo L, Li P, Lei J, Wang J, Zhu B, Wang L, Jia J. Traditional Chinese Medicine Ganshuang Granules Attenuate CCl4 -Induced Hepatic Fibrosis by Modulating Gut Microbiota. Chem Biodivers 2021;18:e2100520. [PMID: 34585845 DOI: 10.1002/cbdv.202100520] [Reference Citation Analysis]
23 Ludgate M. Fibrosis in dysthyroid eye disease. Eye (Lond) 2020;34:279-84. [PMID: 31844169 DOI: 10.1038/s41433-019-0731-5] [Reference Citation Analysis]
24 Gatzios A, Rombaut M, Buyl K, De Kock J, Rodrigues RM, Rogiers V, Vanhaecke T, Boeckmans J. From NAFLD to MAFLD: Aligning Translational In Vitro Research to Clinical Insights. Biomedicines 2022;10:161. [DOI: 10.3390/biomedicines10010161] [Reference Citation Analysis]
25 Li Z, Dong J, Wang M, Yan J, Hu Y, Liu Y, Pan Y, Li H. Resveratrol ameliorates liver fibrosis induced by nonpathogenic Staphylococcus in BALB/c mice through inhibiting its growth. Mol Med 2022;28:52. [PMID: 35508992 DOI: 10.1186/s10020-022-00463-y] [Reference Citation Analysis]
26 Hussain SK, Dong TS, Agopian V, Pisegna JR, Durazo FA, Enayati P, Sundaram V, Benhammou JN, Noureddin M, Choi G, Ayoub WS, Lagishetty V, Elashoff D, Goodman MT, Jacobs JP. Dietary Protein, Fiber and Coffee Are Associated with Small Intestine Microbiome Composition and Diversity in Patients with Liver Cirrhosis. Nutrients 2020;12:E1395. [PMID: 32414035 DOI: 10.3390/nu12051395] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
27 Arsenijevic A, Stojanovic B, Milovanovic J, Arsenijevic D, Arsenijevic N, Milovanovic M. Galectin-3 in Inflammasome Activation and Primary Biliary Cholangitis Development. Int J Mol Sci. 2020;21:5097. [PMID: 32707678 DOI: 10.1038/s41575-019-0226-7] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 16.5] [Reference Citation Analysis]
28 Ma Y, Nenkov M, Chen Y, Press AT, Kaemmerer E, Gassler N. Fatty acid metabolism and acyl-CoA synthetases in the liver-gut axisWorld J Hepatol 2021; 13(11): 1512-1533 [PMID: 34904027 DOI: 10.4254/wjh.v13.i11.1512] [Reference Citation Analysis]
29 Behary J, Amorim N, Jiang XT, Raposo A, Gong L, McGovern E, Ibrahim R, Chu F, Stephens C, Jebeili H, Fragomeli V, Koay YC, Jackson M, O'Sullivan J, Weltman M, McCaughan G, El-Omar E, Zekry A. Gut microbiota impact on the peripheral immune response in non-alcoholic fatty liver disease related hepatocellular carcinoma. Nat Commun 2021;12:187. [PMID: 33420074 DOI: 10.1038/s41467-020-20422-7] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 13.0] [Reference Citation Analysis]
30 Yan Z, Yang F, Hong Z, Wang S, Jinjuan Z, Han B, Xie R, Leng F, Yang Q. Blueberry Attenuates Liver Fibrosis, Protects Intestinal Epithelial Barrier, and Maintains Gut Microbiota Homeostasis. Can J Gastroenterol Hepatol 2019;2019:5236149. [PMID: 31886154 DOI: 10.1155/2019/5236149] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
31 Sánchez-Monteagudo A, Ripollés E, Berenguer M, Espinós C. Wilson's Disease: Facing the Challenge of Diagnosing a Rare Disease. Biomedicines 2021;9:1100. [PMID: 34572285 DOI: 10.3390/biomedicines9091100] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
32 Wells AI, Grimes KA, Kim K, Branche E, Bakkenist CJ, DePas WH, Shresta S, Coyne CB. Human FcRn expression and Type I Interferon signaling control Echovirus 11 pathogenesis in mice. PLoS Pathog 2021;17:e1009252. [PMID: 33513208 DOI: 10.1371/journal.ppat.1009252] [Reference Citation Analysis]
33 Tsai YT, Ruan JW, Chang CS, Ko ML, Chou HC, Lin CC, Lin CM, Huang CT, Wei YS, Liao EC, Chen HY, Lin LH, Lin MW, Kao CY, Chan HL. Proteomic and microbial assessments on the effect of Antrodia cinnamomea in C57BL/6 mice. Arch Biochem Biophys 2021;713:109058. [PMID: 34627749 DOI: 10.1016/j.abb.2021.109058] [Reference Citation Analysis]
34 Zhang C, Yang M, Ericsson AC. The Potential Gut Microbiota-Mediated Treatment Options for Liver Cancer. Front Oncol 2020;10:524205. [PMID: 33163393 DOI: 10.3389/fonc.2020.524205] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
35 Liang Q, Zhang M, Hu Y, Zhang W, Zhu P, Chen Y, Xue P, Li Q, Wang K. Gut Microbiome Contributes to Liver Fibrosis Impact on T Cell Receptor Immune Repertoire. Front Microbiol 2020;11:571847. [PMID: 33329430 DOI: 10.3389/fmicb.2020.571847] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
36 Saiki H, Okano Y, Yasuma T, Toda M, Takeshita A, Abdel-Hamid AM, Fridman D'Alessandro V, Tsuruga T, D'Alessandro-Gabazza CN, Katayama K, Sugimoto M, Fujimoto H, Yamanaka K, Kobayashi T, Cann I, Gabazza EC. A Microbiome-Derived Peptide Induces Apoptosis of Cells from Different Tissues. Cells 2021;10:2885. [PMID: 34831108 DOI: 10.3390/cells10112885] [Reference Citation Analysis]
37 Tranah TH, Edwards LA, Schnabl B, Shawcross DL. Targeting the gut-liver-immune axis to treat cirrhosis. Gut 2021;70:982-94. [PMID: 33060124 DOI: 10.1136/gutjnl-2020-320786] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
38 Micó-Carnero M, Casillas-Ramírez A, Caballeria-Casals A, Rojano-Alfonso C, Sánchez-González A, Peralta C. Role of Dietary Nutritional Treatment on Hepatic and Intestinal Damage in Transplantation with Steatotic and Non-Steatotic Liver Grafts from Brain Dead Donors. Nutrients 2021;13:2554. [PMID: 34444713 DOI: 10.3390/nu13082554] [Reference Citation Analysis]
39 Arsenijevic A, Stojanovic B, Milovanovic J, Arsenijevic D, Arsenijevic N, Milovanovic M. Galectin-3 in Inflammasome Activation and Primary Biliary Cholangitis Development. Int J Mol Sci 2020;21:E5097. [PMID: 32707678 DOI: 10.3390/ijms21145097] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
40 Yang M, Zhang CY. G protein-coupled receptors as potential targets for nonalcoholic fatty liver disease treatment. World J Gastroenterol 2021; 27(8): 677-691 [PMID: 33716447 DOI: 10.3748/wjg.v27.i8.677] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
41 Dong L, Xie J, Wang Y, Zuo D. Gut Microbiota and Immune Responses. Adv Exp Med Biol 2020;1238:165-93. [PMID: 32323185 DOI: 10.1007/978-981-15-2385-4_10] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
42 Glaser T, Baiocchi L, Zhou T, Francis H, Lenci I, Grassi G, Kennedy L, Liangpunsakul S, Glaser S, Alpini G, Meng F. Pro-inflammatory signalling and gut-liver axis in non-alcoholic and alcoholic steatohepatitis: Differences and similarities along the path. J Cell Mol Med. 2020;24:5955-5965. [PMID: 32314869 DOI: 10.1111/jcmm.15182] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
43 Sepulveda-Crespo D, Resino S, Martinez I. Strategies Targeting the Innate Immune Response for the Treatment of Hepatitis C Virus-Associated Liver Fibrosis. Drugs 2021;81:419-43. [PMID: 33400242 DOI: 10.1007/s40265-020-01458-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
44 Muthuramalingam K, Kim Y, Cho M. β-glucan, "the knight of health sector": critical insights on physiochemical heterogeneities, action mechanisms and health implications. Crit Rev Food Sci Nutr 2021;:1-37. [PMID: 33819119 DOI: 10.1080/10408398.2021.1908221] [Cited by in F6Publishing: 1] [Reference Citation Analysis]